Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04051502 · ClinicalTrials.gov registry record · Early Phase 1
ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study
A Early Phase 1 study of Ovarian Cancer and Adnexal Mass, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 48
- Enrollment target
- 7
- Study locations
NCT04051502 is a Early Phase 1 study of Ovarian Cancer and Adnexal Mass that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 48 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT04051502, a Early Phase 1 study of Ovarian Cancer and Adnexal Mass, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 48 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out how well ovarian sentinel lymph nodes (SLNs) can be identified with indocyanine green (ICG) dye during risk-reducing ovarian surgery.
Conditions Studied
Interventions
- DRUG Method 1: Indocyanine green dye
- DRUG Method 2: Indocyanine green dye
- DRUG Method 3: Indocyanine green dye
Study Locations (7)
New York
- Memorial Sloan Kettering Commack (Consent only) - Commack
- Memorial Sloan Kettering Westchester (Consent only) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Consent only) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Consent only) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent only) - Middletown
- Memorial Sloan Kettering Bergen (Consent only ) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2025-12-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04051502
The ClinicalTrials.gov registry entry for NCT04051502 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which Method 1: Indocyanine green dye is the first listed.
NCT04051502 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04051502 about?
NCT04051502 is a clinical study titled "ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study". The purpose of this study is to find out how well ovarian sentinel lymph nodes (SLNs) can be identified with indocyanine green (ICG) dye during risk-reducing ovarian surgery.
What is the current status of trial NCT04051502?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 48 participants. The study started on 2019-08-05. Estimated completion is 2025-12-08.
What conditions does trial NCT04051502 study?
This clinical trial studies the following conditions: Ovarian Cancer, Adnexal Mass.
What interventions are being tested in trial NCT04051502?
The interventions under investigation include: Method 1: Indocyanine green dye (DRUG), Method 2: Indocyanine green dye (DRUG), Method 3: Indocyanine green dye (DRUG).
Who is sponsoring clinical trial NCT04051502?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04051502 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Aspirin to Improve Immunological Features of Ovarian Tumors
RECRUITING · Early Phase 1
-
Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer
COMPLETED · Early Phase 1
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.